TheraVet: Significant Sales Progression for BIOCERA-VET® in Q3 2023
November 08 2023 - 1:30AM
Business Wire
- Over 75% progression of BIOCERA-VET® line sales, including 300%
increase in BIOCERA-VET® OSTEOSARCOMA
- Symbolic milestone of 1,000 units sold crossed
- Confirmed success of the recently launched BIOCERA-VET®
references
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
announces significant progression for BIOCERA-VET® line in the
third quarter of 2023.
The number of BIOCERA-VET® units sold increased by 79% in
the third quarter 2023 as compared to the same period in 2022 and
by 39% as compared to the second quarter of 2023.
BIOCERA-VET® BONE SURGERY1 accounted for 82% of the units sold and
BIOCERA-VET® OSTEOSARCOMA RTU for the remaining 18%. The recently
launched references BONE SURGERY RTU 3*1cc, and OSTEOSARCOMA RTU
2*12cc have significantly contributed to these figures. This is
particularly reflected in the impressive BIOCERA-VET® OSTEOSARCOMA
RTU sales progression of 300% as compared to Q3 2022. BIOCERA-VET®
BONE SURGERY unit sales are also up 60% compared to Q3 2022 and up
75% compared to Q2 2023. Geographically, Europe drives the sales
with 79% of the units sold in the third quarter of 2023 while North
America (USA and Canada) - progressing fast - now accounts for 19%
of the units sold.
These very good figures results from the Company important
commercial efforts and the participation at European and
international conferences (gathering the surgery and oncology
specialist customers) increasing the visibility and awareness of
BIOCERA-VET® line. More specifically, for BIOCERA-VET® OSTEOSARCOMA
RTU, the significant increase in sales resulted from TheraVet
OSTEOSARCOMA Program implemented in 2023 with among others, its
dedicated platform www.bonecancer.dog. This progression led to a
net increase of requests related to the usage of BIOCERA-VET® from
owners and from veterinarians relying on our expertise and
technical support.
Also, the recent launch of BIOCERA-VET® COMBO CLEAN in Europe in
end of May as well as the increase of coverage of distribution in
New Zealand, Slovakia, Czech Republic and Norway also contributed
to these figures.
All these factors enabled the Company to cross the symbolic
milestone of 1,000 BIOCERA-VET® units sold.
The Company will continue its commercial efforts by attending in
the last quarter of the year 4 conferences, including 2 in Belgium
(Vétérinexpo and Expovet), 1 in France (Association Française des
Vétérinaires pour Animaux de Compagnie, or AFVAC) and 1 in the
United Kingdom (London Vet Show, or LVS) all representing the
largest gathering of veterinarians in these countries. For AFVAC
and LVS, the Company presents alongside French and British
BIOCERA-VET® distributors (i.e., Elvetis and Veterinary
Instrumentation). Webinars are also planned.
Enrico Bastianelli, Chief Executive Officer, stated: “The
sales dynamic of the BIOCERA-VET® product range, and in particular
the spectacular jump in BIOCERA-VET® OSTEOSARCOMA units sold, is
the result of a successful positioning on high-potential
indications and of a perfect execution by TheraVet marketing and
sales teams. TheraVet relentless promotional efforts are supported
by the increasing acknowledgement of its scientific credibility
thanks to its ever-growing network of users (KOLs and renowned
veterinarians) and its increasingly complete collection of clinical
cases. Finally, the owners' leverage - built on the network of
OSTEOSARCOMA centers launched last April - is starting to bear
fruit, by accelerating the demand for cementoplasty in canine
osteosarcoma.”
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
About BIOCERA-VET In close collaboration with an
international scientific board, THERAVET® has developed a new line
of calcium-phosphate and biological bone substitutes, BIOCERA-VET®.
BIOCERA-VET® is a full range of innovative, easy-to-use, efficient
& cost-effective bone substitutes indicated in bone surgeries
where a bone graft is required and as a palliative alternative in
the management of canine osteosarcoma. Based on extremely promising
clinical results, this line offers the possibility of a better,
more convenient and more efficient orthopedic surgery. BIOCERA-VET®
is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
1 BIOCERA-VET BONE SURGERY (BS) line includes 5 references: BS
RTU 1cc, BS RTU 3cc, BS RTU 3*1cc, Granules and Smartgraft
products
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107082764/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Apr 2024 to May 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From May 2023 to May 2024